Cohen, S. J., Zalupski, M. M., Modiano, M. R., Conkling, P. R., Patt, Y. Z., Davis, P., … Hersh, E. M. (2008). A phase I study of imexon inj plus gemcitabine as first-line therapy for advanced pancreatic cancer with preclinical mechanistic study of dose limiting toxicity. In Journal of Clinical Oncology (Vol. 26, pp. 4619–4619). American Society of Clinical Oncology (ASCO). https://doi.org/10.1200/jco.2008.26.15_suppl.4619

Cohen, S. J., M. M. Zalupski, M. R. Modiano, P. R. Conkling, Y. Z. Patt, P. Davis, R. T. Dorr, M. L. Boytim, and E. M. Hersh. “A phase I study of imexon inj plus gemcitabine as first-line therapy for advanced pancreatic cancer with preclinical mechanistic study of dose limiting toxicity.” In Journal of Clinical Oncology, 26:4619–4619. American Society of Clinical Oncology (ASCO), 2008. https://doi.org/10.1200/jco.2008.26.15_suppl.4619.

Cohen SJ, Zalupski MM, Modiano MR, Conkling PR, Patt YZ, Davis P, et al. A phase I study of imexon inj plus gemcitabine as first-line therapy for advanced pancreatic cancer with preclinical mechanistic study of dose limiting toxicity. In: Journal of Clinical Oncology. American Society of Clinical Oncology (ASCO); 2008. p. 4619–4619.

Cohen, S. J., et al. “A phase I study of imexon inj plus gemcitabine as first-line therapy for advanced pancreatic cancer with preclinical mechanistic study of dose limiting toxicity.” Journal of Clinical Oncology, vol. 26, no. 15_suppl, American Society of Clinical Oncology (ASCO), 2008, pp. 4619–4619. Crossref, doi:10.1200/jco.2008.26.15_suppl.4619.

Cohen SJ, Zalupski MM, Modiano MR, Conkling PR, Patt YZ, Davis P, Dorr RT, Boytim ML, Hersh EM. A phase I study of imexon inj plus gemcitabine as first-line therapy for advanced pancreatic cancer with preclinical mechanistic study of dose limiting toxicity. Journal of Clinical Oncology. American Society of Clinical Oncology (ASCO); 2008. p. 4619–4619.